You can buy or sell INFI and other stocks, options, ETFs, and crypto commission-free!
Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. Read More The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMar 15
Infinity Inks Deal With Roche for Phase II Study of IPI-549
Shares of Infinity Pharmaceuticals Inc. INFI rose almost 24% after the company announced that it has entered into a master clinical supply agreement with Roche RHHBY. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity for use in MARIO-3, a phase II multi-arm combination cohort study. The study will evaluate Infinity’s lead immuno-oncology candidate, IPI-549in combination with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC), and IPI-549 in combinat...
Seeking AlphaMar 14
Infinity Pharmaceuticals beats by $0.03, revenue in-line - Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)
Markets InsiderMar 14
Infinity Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Company Update
CAMBRIDGE, Mass., March 14, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its full year 2018 financial results and provided an update on the company, including its progress with IPI-549, a first-in-class oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition. Today, Infinity also announced MARIO-3, a Phase 2 study in collaboration with Roche, which will e...
-$0.17 per share
-$0.14 per share